

CURRICULUM VITAE

PERSONAL DETAILS

Name and Surname: Manuela Mancini

Birth date: July 8th, 1978

Place of Birth: Messina

Nationality: Italian

Telephone Number: mobile: +39-339-5008394

E-mail: mancini_manu@yahoo.com, manuela.mancini6@unibo.it, mancini.manuela@aosp.bo.it

Orcid: 0000-0002-2972-5609

PRESENT POSITION

Health Researcher, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Supervisor: Prof. Michele Cavo.

AFFILIATION

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy

EDUCATION

- December 2010: Post Graduation Degree in Clinical Biochemistry. University of Modena and Reggio Emilia, Italy. 110/110 cum laude. Thesis title: "Fighting leukemic stem cells: the new challenge in targeted therapy of Chronic Myeloid Leukemia" Supervisor: Prof. Maria Alessandra Santucci.
- May 2005: PhD in "Molecular and Cellular Biotechnology". Thesis title: "P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes", University of Bologna, Italy. Supervisor: Prof. Rita Casadio.
- July 2001: Graduation Degree in Biotechnology, University of Bologna, Italy. 110/110. Thesis title: "Biomolecular pathways involved in abrogation of G1/S and G2/M checkpoints associated with BCR-ABL expression in Chronic myeloid leukemia". Supervisor: Prof. Maria Alessandra Santucci.

FOREIGN LANGUAGE

- English: intermediate

RESEARCH FOCUS AND EXPERTISE:

Chronic Myeloid Leukemia; Systemic Mastocytosis; molecular and cellular mechanisms of resistance to targeted therapies.

MEMBERSHIP OF SCIENTIFIC ASSOCIATIONS•

Member of the Italian Society of Experimental Hematology (SIES), the European Hematology Association (EHA).

PARTICIPATION IN NATIONAL RESEARCH PROJECTS FUNDED ON A COMPETITIVE BASIS

- Scientific collaborator of a 2019 IG Grant of the Italian Association for Cancer Research (AIRC): "ReSETting SETD2/H3K36Me3 deficiency in advanced systemic mastocytosis and chronic myeloid leukemia" (Project Id.23001)
- Co-Principal Investigator of the project funded by Ministry of Health:"BCR-ABL MUTATION INDEPENDENT MECHANISMS INVOLVED IN RESISTANCE TO TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA", (Project Id.GR-2016-02364880)
- Scientific collaborator of a 2015 AIRC IG Grant: "High throughput technologies for improved diagnosis, molecular profiling and therapy of systemic mastocytosis" (Project Id.16996)

COLLABORATION IN JOURNAL EDITORIAL BOARDS

Guest Editor of:

Special Issue: "CML HSCs: are the true enemies for the patient?" *Current Drug Targets* 2017 IF: 2.5

Topic co-Editor of:

Research Topic "Chronic Myeloid Leukemia: From Targeted Therapy to Treatment-Free Remission" *Frontiers in Pharmacology*, 2025 IF: 4.8

REVIEWER ACTIVITY

Manuscript reviewer for international journals (BMC cancer, Leukemia research, Scientific Reports, PlosOne, The European Journal of Pharmacology)

PARTICIPATION IN NATIONAL AND INTERNATIONAL MEETINGS AS SPEAKER

Speaker at 60 national and international meetings.

AWARDS

2010 SIES Award for the project: "THE ROLE OF CHIBBY HAPLOINSUFFICIENCY, ORIGINATED BY GENE DELETION AT CHROMOSOME 22 q13.1, IN THE PATHOGENESIS AND PROGRESSION OF CHRONIC MYELOID LEUKEMIA"

2011 Fondazione Umberto Veronesi Award as Young Investigator for the project: "THE ROLE OF BETA CATENIN ANTAGONIST CHIBBY IN THE PATHOGENESIS AND PROGRESSION OF CHRONIC MYELOID LEUKEMIA"

2012 Fondazione Umberto Veronesi Award as Young Investigator for the project: "THE ROLE OF BETA CATENIN ANTAGONIST CHIBBY IN THE PATHOGENESIS AND PROGRESSION OF CHRONIC MYELOID LEUKEMIA"

2013 Fondazione Umberto Veronesi Award as Young Investigator for the project: "THE ROLE OF FOXM1 HYPERACTIVATION IN CML STEM CELL PROLIFERATION AND SURVIVAL"

2014 Fondazione Umberto Veronesi Award as Young Investigator for the project: "THE ROLE OF FOXM1 HYPERACTIVATION IN CML STEM CELL PROLIFERATION AND SURVIVAL"

2017 ASH Abstract Achievement Award for the abstract: Mancini et al. "SETD2 Loss of Function is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia" (presented at the 2017 ASH annual meeting)

PUBLICATIONS•

First or contributing author of 60 publications in peer-reviewed journals; h index: 22 (Scopus, 20/02/2025)

1. BRUSA G, BENVENUTI M, MAZZACURATI L, **MANCINI M**, PATTACINI L, MARTINELLI G, BARBIERI E, GREENBERGER JS, BACCARANI M, SANTUCCI MA. P53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p²¹⁰bcr-abl tyrosine kinase. *Haematologica* 2003, 88:622-630.
2. MAZZACURATI L, PATTACINI L, BRUSA G, **MANCINI M**, BENVENUTI M, BARBIERI E, MARTINELLI G, BACCARANI M, SANTUCCI MA. Chk2 drives late G₁/early S phase arrest in response to STI571 of clonal myeloid progenitors expressing the p210 bcr-abl tyrosine kinase. *The Hematology Journal*, 2004; 5(2): 168-177.
3. PATTACINI L, **MANCINI M**, MAZZACURATI L, BRUSA G, BENVENUTI M, CAMPANINI F, BACCARANI M, SANTUCCI MA. Endoplasmic reticulum stress initiates apoptotic death of chronic myeloid leukemia progenitors by STI571. *Leukemia Research*, 2004, Feb; 28 (2): 191-202.
4. **MANCINI M.**, BRUSA G, BENVENUTI M., MAZZACURATI L., CAMPANINI F., BARBIERI E., CAMMELLI S., CALONGHI N., MARTINELLI G., BACCARANI M., SANTUCCI MA. The p210 bcr-abl tyrosine kinase of Chronic Myeloid Leukemia causes resistance to radio-induced apoptotic death by inhibiting pro-apoptotic Bax gene. *Leukemia*, 2004 Feb; 18 (2): 370-372.
5. GIANLUCA BRUSA, **MANUELA MANCINI**, FABIO CAMPANINI, ALBERTO CALABRÒ, ELISA ZUFFA, ENZA BARBIERI, MARIA ALESSANDRA SANTUCCI. Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild type p53 on k562 cell line to enhance its pro-apoptotic effects. *Acta Haematologica*, 2005; 114(3): 150-154.

6. GIANLUCA BRUSA, **MANUELA MANCINI**, ELISA ZUFFA, VALERIA GHETTI, ENZA BARBIERI, MARIA ALESSANDRA SANTUCCI. Ectopic expression of p210 BCR-ABL tyrosine kinase of Chronic Myeloid Leukemia downregulates DR4 receptor expression. *European journal of oncology*, 2005;10(3):199-206.
7. **MANCINI M.**, CALONGHI N., PAGNOTTA E., MASOTTI L., BRUSA G., ZUFFA E., CALABRO' A., BARBIERI E., SANTUCCI MA. P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes. *Gene Therapy and Molecular Biology*, 2005;9:359-370.
8. BRUSA G., ZUFFA E., MANCINI M., BENVENUTI M., CALONGHI N., BARBIERI E., SANTUCCI MA. P210 BCR-ABL tyrosine kinase interaction with Histone Deacetylase (Hdac)1 modifies histone H4 acetylation and chromatin structure of Chronic Myeloid Leukaemia hematopoietic progenitors. *Br J Haematol*, 2006 Feb;132(3):359-69.
9. **MANCINI M.**, BRUSA G., ZUFFA E., CORRADO P., MARTINELLI G., GRAFONE T., BARBIERI E., SANTUCCI MA. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. *Leukemia Research*, 2007 Jul;31(7):979-87.
10. BRUSA G, ZUFFA E, HATTINGER CM, SERRA M, REMONDINI D, CASTELLANI G, RIGHI S, CAMPIDELLI C, PILERI S, ZINZANI PL, GABRIELE A, **MANCINI M**, CORRADO P, BARBIERI E, SANTUCCI MA. Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. *Oncol Rep*. 2007 Dec;18(6):1427-34.
11. **MANCINI M**, ZUFFA E, VELJKOVIC N, BRUSA G, CORRADO P, CORRADI V, MARTINELLI G, BARBIERI E, SANTUCCI MA. IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia. *Br J Haematol*. 2008 Jun;141(6):899-902. Epub 2008 Mar 27.
12. RADII M, CRESPIAN E, BOTTA G, FALCHI F, MAGA G, MANETTI F, CORRADI V, **MANCINI M**, SANTUCCI MA, SCHENONE S, BOTTA M. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. *Bioorg Med Chem Lett*. 2008 Feb 1;18(3):1207-11. Epub 2007 Dec 4.
13. ZUFFA E., **MANCINI M.**, BRUSA G., PAGNOTTA E., HATTINGER CM., SERRA M., REMONDINI D., CASTELLANI G., CORRADO P., BARBIERI E., SANTUCCI MA. P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2. *Int J Radiat Biol*. 2008 Jul;84(7):591-601.
14. CORRADO P, **MANCINI M**, BRUSA G, PETTA S, MARTINELLI G, BARBIERI E, SANTUCCI MA. Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia. *Leukemia*. 2009 Feb;23(2):405-6.
15. SANTUCCI MA, CORRADI V, **MANCINI M**, MANETTI F, RADII M, SCHENONE S, BOTTA M. C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. *ChemMedChem*. 2009 Jan;4(1):118-26.

16. **MANUELA MANCINI**, NEVENA VELJKOVIC, VALENTINA CORRADI, ELISA ZUFFA, PATRIZIA CORRADO, ELEONORA PAGNOTTA, GIOVANNI MARTINELLI, ENZA BARBIERI, MARIA ALESSANDRA SANTUCCI. Binding to the 14-3-3 scaffolding protein prevents the pro-apoptotic activity of c-Abl in chronic myeloid leukemia. *Traffic*, 2009 Jun;10(6):637-47. Epub 2009 Feb 11.
17. **MANCINI M**, CORRADI V, PETTA S, MARTINELLI G, BARBIERI E, SANTUCCI MA. MTOR inhibitor RAD001 (Everolimus) enhances the effects of Imatinib in chronic myeloid leukaemia by raising the nuclear expression of c-Abl protein. *Leukemia Research*. 2009 Jul 28. [Epub ahead of print].
18. SANTUCCI MA, **MANCINI M**, CORRADI V, IACOBUCCI I, MARTINELLI G, BOTTA M, SCHENONE S. New Src/Abl inhibitors for chronic myeloid leukemia therapy show selectivity for T315I Abl mutant CD34(+) cells. *Invest new drugs*. 2009 Jul 24. [Epub ahead of print].
19. **MANCINI M**, PETTA S, MARTINELLI G, BARBIERI E, SANTUCCI MA. RAD001 (Everolimus) prevents mTOR and AKT late reactivation in response to Imatinib in chronic myeloid leukaemia. *J Cell Biochem*. 2010 Feb 1;109(2):320-8.
20. **MANCINI M**, PETTA S, IACOBUCCI I., SALVESTRINI V., BARBIERI E., SANTUCCI MA. Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. *Cell Signal*. 2010 Apr 11. [Epub ahead of print].
21. CORRADI V, **MANCINI M**, MANETTI F, PETTA S, SANTUCCI MA, BOTTA M. Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. *Bioorg Med Chem Lett*. 2010 Aug 8. [Epub ahead of print].
22. AGOSTINELLI C, SABATTINI E, GJØRRET JO, RIGHI S, ROSSI M, **MANCINI M**, PICCALUGA PP, BACCI F, MARAFIOTI T, BETTINI G, FALINI B, PILERI SA. Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples. *Appl Immunohistochem Mol Morphol*. 2010 Aug 6. [Epub ahead of print].
23. **MANCINI M.**, CORRADI V., PETTA S., BARBIERI E., MANETTI F., BOTTA M., SANTUCCI MA. A new non-peptidic inhibitor of the 14-3-3 docking site induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to Imatinib. *J Pharmacol Exp Ther*. 2010 Nov 1. [Epub ahead of print].
24. ALVISI G, MARIN O, PARI G, **MANCINI M**, AVANZI S, LOREGIAN A, JANS DA, RIPALTI A. Multiple phosphorylation sites at the C-terminus regulate nuclear import of HCMV DNA polymerase processivity factor ppUL44. *Virology*. 2011 Sep 1;417(2):259-67. Epub 2011 Jul 8.
25. CORRADI V, **MANCINI M**, **SANTUCCI MA**, CARLOMAGNO T, SANFELICE D, MORI M, VIGNAROLI G, FALCHI F, MANETTI F, RADU M, BOTTA M. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: The 14-3-3 σ case. *Bioorg Med Chem Lett*. 2011 Sep 10. [Epub ahead of print]

26. **MANCINI M**, ALUIGI M, LEO E, MARCOZZI C, CASTAGNETTI F, BARBIERI E, SANTUCCI MA. Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457. *Br J Haematol.* 2012 Jan;156(2):265-8. Epub 2011 Nov 22.
27. **MANCINI M**, VELJKOVIC N, LEO E, ALUIGI M, BORSI E, GALLONI C, IACOBUCCI I, BARBIERI E, SANTUCCI MA. Cytoplasmic compartmentalization by BCR-ABL promotes TET2 loss-of-function in chronic myeloid leukemia. *J Cell Biochem.* 2012 Mar 30.
28. **MANCINI M**, LEO E, ALUIGI M, MARCOZZI C, BORSI E, BARBIERI E, SANTUCCI MA. Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor. *Leuk Res.* 2012 Aug;36(8):1028-34. Epub 2012 Apr 20.
29. LEO E, **MANCINI M**, ALUIGI M, CASTAGNETTI F, MARTINELLI G, BARBIERI E, SANTUCCI MA. DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia. *Br J Haematol.* 2012 Aug 25.
30. **MANCINI M**, LEO E, TAKEMARU KI, CAMPI V, BORSI E, CASTAGNETTI F, GUGLIOTTA G, SANTUCCI MA, MARTINELLI G. "Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells". *Cell Signal* (2013).
31. ELISA LEO, **MANUELA MANCINI**, MICHELA ALUIGI, SIMONA LUATTI, FAUSTO CASTAGNETTI, NICOLETTA TESTONI, SIMONA SOVERINI, MARIA ALESSANDRA SANTUCCI, GIOVANNI MARTINELLI. "BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia". *PLOS ONE*, Dec 10;8(12):e81425.
32. **MANCINI M**, LEO E, CAMPI V, CASTAGNETTI F, ZAZZERONI L, GUGLIOTTA G, SANTUCCI MA, MARTINELLI G. A calpain-cleaved fragment of β -catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib. *Cell Signal.* 2014 Aug;26(8):1690-7. doi: 10.1016/j.cellsig.2014.04.010. Epub 2014 Apr 18.
33. PICCALUGA PP, ROSSI M, AGOSTINELLI C, RICCI F, GAZZOLA A, RIGHI S, FULIGNI F, LAGINESTRA MA, **MANCINI M**, SAPIENZA MR, DE RENZO A, TAZZARI PL, GIBELLINI D, WENT P, ALVIANO F, ZINZANI PL, BAGNARA GP, INGHIRAMI G, TRIPODO C, PILERI SA. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. *Leukemia.* 2014 Aug;28(8):1687-97. doi: 10.1038/leu.2014.50. Epub 2014 Jan 31.
34. SAPIENZA MR, FULIGNI F, AGOSTINELLI C, TRIPODO C, RIGHI S, LAGINESTRA MA, PILERI A JR, **MANCINI M**, ROSSI M, RICCI F, GAZZOLA A, MELLE F, MANNU C, ULBAR F, ARPINATI M, PAULLI M, MAEDA T, GIBELLINI D, PAGANO L, PIMPINELLI N, SANTUCCI M, CERRONI L, CROCE CM, FACCHETTI F, PICCALUGA PP, PILERI SA; AIRC 5XMILLE CONSORTIUM 'GENETICS-DRIVEN TARGETED MANAGEMENT OF LYMPHOID MALIGNANCIES AND THE ITALIAN REGISTRY ON BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF- κ B pathway inhibition. *Leukemia.* 2014 Aug;28(8):1606-16. doi: 10.1038/leu.2014.64. Epub 2014 Feb 7.

35. LEO E, **MANCINI M**, CASTAGNETTI F, GUGLIOTTA G, SANTUCCI MA, MARTINELLI G. DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. *J Cell Biochem*. 2015 Apr;116(4):589-97. doi: 10.1002/jcb.25010.
36. **MANCINI M**, LEO E, TAKEMARU K, CAMPI V, CASTAGNETTI F, SOVERINI S, DE BENEDITTIS C, ROSTI G, CAVO M, SANTUCCI MA, MARTINELLI G. 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β -catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. *PLoS One*. 2015 Jul 6;10(7):e0131074. doi: 10.1371/journal.pone.0131074. eCollection 2015.
37. SOVERINI S, DE BENEDITTIS C, **MANCINI M**, MARTINELLI G. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2015 Jun;15 Suppl:S120-8. doi: 10.1016/j.clml.2015.02.035. Review.
38. SOVERINI S, DE BENEDITTIS C, PAPAYANNIDIS C, POLAKOVA KM, VENTURI C, RUSSO D, BRESCIANI P, IURLO A, **MANCINI M**, VITALE A, CHIARETTI S, FOÀ R, ABRUZZESE E, SORÀ F, KOHLMANN A, HAFERLACH T, BACCARANI M, CAVO M, MARTINELLI G. Clinical impact of low burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. *Leukemia*. 2016 Feb 12.
39. SOVERINI S, DE BENEDITTIS C, CASTAGNETTI F, GUGLIOTTA G, **MANCINI M**, BAVARO L, MACHOVA POLAKOVA K, LINHARTOVA J, IURLO A, RUSSO D, PANE F, SAGLIO G, ROSTI G, CAVO M, BACCARANI M, MARTINELLI G. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. *BMC Cancer*. 2016 Aug 2;16:572.
40. SOVERINI S, DE BENEDITTIS C, **MANCINI M**, MARTINELLI G. Best Practices in Chronic Myeloid Leukemia Monitoring and Management. *Oncologist*. 2016 May;21(5):626-33. Review.
41. SOVERINI S, DE BENEDITTIS C, POLAKOVA KM, LINHARTOVA J, CASTAGNETTI F, GUGLIOTTA G, PAPAYANNIDIS C, **MANCINI M**, KLAMOVA H, SALVUCCI M, CRUGNOLA M, IURLO A, ALBANO F, RUSSO D, ROSTI G, CAVO M, BACCARANI M, MARTINELLI G. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. *Oncotarget*. 2016 Apr 19;7(16):21982-90.
42. SOVERINI S, DE BENEDITTIS C, **MANCINI M**, MARTINELLI G. Present and future of molecular monitoring in chronic myeloid leukaemia. *Br J Haematol*. 2016 May;173(3):337-49. Review.
43. **MANCINI M**, CASTAGNETTI F, SOVERINI S, LEO E, DE BENEDITTIS C, GUGLIOTTA G, ROSTI G, BAVARO L, DE SANTIS S, MONALDI C, MARTELLI M, SANTUCCI MA, CAVO M, MARTINELLI G. FOXM1 TRANSCRIPTION FACTOR: A NEW COMPONENT OF CHRONIC MYELOID LEUKEMIA STEM CELL PROLIFERATION ADVANTAGE. *J Cell Biochem*. 2017 Apr 12.
44. MARTINELLI G, **MANCINI M**, DE BENEDITTIS C, RONDONI M, PAPAYANNIDIS C, MANFRINI M, MEGGENDORFER M, CALOGERO R, GUADAGNUOLO V, FONTANA MC, BAVARO L, PADELLA A, ZAGO E, PAGANO L, ZANOTTI R, SCAFFIDI L, SPECCHIA G, ALBANO F, MERANTE S, ELENA

- C, SAVINI P, GANGEMI D, TOSI P, CICERI F, POLETTI G, RICCIONI L, MORIGI F, DELLEDONNE M, HAFERLACH T, CAVO M, VALENT P, SOVERINI S. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. *Leukemia*. 2017 Jun 16.
45. **MANCINI M**, SOVERINI S, GUGLIOTTA G, SANTUCCI MA, ROSTI G, CAVO M, MARTINELLI G, CASTAGNETTI F. Chibby 1: a new component of β -catenin-signaling in chronic myeloid leukemia. *Oncotarget*. 2017 Sep 22;8(50):88244-88250. 2017 Oct 20. Review.
 46. **SOVERINI S, MANCINI M**, BAVARO L, CAVO M, MARTINELLI G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. *Mol Cancer*. 2018 Feb 19;17(1):49. Review.
 47. **MANCINI M**, DE SANTIS S, MONALDI C, BAVARO L, MARTELLI M, CASTAGNETTI F, GUGLIOTTA G, ROSTI G, SANTUCCI MA, MARTINELLI G, CAVO M, SOVERINI S. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. *J Exp Clin Cancer Res*. 2019 May 23;38(1):216. **IF:**
 48. **MANCINI M**, DE SANTIS S, MONALDI C, BAVARO L, MARTELLI M, GUGLIOTTA G, CASTAGNETTI F, ROSTI G, SANTUCCI MA, MARTINELLI G, CAVO M, SOVERINI S. Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis. *Hematol Oncol*. 2020 Jan 28.
 49. MARTELLI M, MONALDI C, DE SANTIS S, BRUNO S, **MANCINI M**, CAVO M, SOVERINI S. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy. *Int J Mol Sci*. 2020 Jun 2;21(11):3987. Review.
 50. BRUNO S., **MANCINI M.**, DE SANTIS S., MONALDI C., CAVO M., SOVERINI S. (2021). The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*, vol. 22, p. 1-18.
 51. SOVERINI S., DE SANTIS S., MONALDI C., BRUNO S., **MANCINI M.** (2021). Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort? *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*, vol. 22, p. 7093-7115.
 52. Monaldi C., de Santis S., **Mancini M.**, Bruno S., Cavo M., Soverini S. (2021). Systemic mastocytosis: Molecular landscape and implications for treatment. *MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES*, vol. 13, p. e2021046.
 53. Bruno S., Bandini L., Patuelli A., Robustelli V., Venturi C., **Mancini M.**, Forte D., De Santis S., Monaldi C., Grassi A., Chiurumbolo G., Paolini S., Cristiano G., Papayannidis C., Sartor C., Nanni J., Ottaviani E., Curti A., Cavo M., Soverini S. (2021). Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. *FRONTIERS IN ONCOLOGY*, vol. 11, p. 728613-728619.
 54. **Mancini M**, De Santis S, Monaldi C, Castagnetti F, Lonetti A, Bruno S, Dan E, Sinigaglia B, Rosti G, Cavo M, Gugliotta G, Soverini S (2022). Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. *FRONTIERS IN ONCOLOGY*, vol. 12, p. 901132-901144.
 55. De Santis S., Monaldi C., **Mancini M.**, Bruno S., Cavo M., Soverini S. (2022). Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. *ONCOTARGETS AND THERAPY*, vol. 15, p. 103-116.

56. **Mancini M.**, Monaldi C., De Santis S., Rondoni M., Papayannidis C., Sartor C., Curti A., Bruno S., Cavo M., Soverini S. (2022). Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells. *CANCERS*, vol. 14, p. 738-750.
57. IEZZA M, CORTESI S, OTTAVIANI E, **MANCINI M**, VENTURI C, MONALDI C, DE SANTIS S, TESTONI N, SOVERINI S, ROSTI G, CAVO M, CASTAGNETTI F. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights. *Cells*. 2023 Jun 23;12(13):1703. doi: 10.3390/cells12131703.Review.
58. **MANCINI M**, MONALDI C, DE SANTIS S, PAPAYANNIDIS C, RONDONI M, SARTOR C, BRUNO S, PAGANO L, CRISCUOLO M, ZANOTTI R, BONIFACIO M, TOSI P, AROCK M, VALENT P, CAVO M, SOVERINI S. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted. *Biomark Res*. 2023 Mar 10;11(1):29. doi: 10.1186/s40364-023-00468-7.
59. BRUNO S, BORSI E, PATUELLI A, BANDINI L, **MANCINI M**, FORTE D, NANNI J, BARONE M, GRASSI A, CRISTIANO G, VENTURI C, ROBUSTELLI V, ATZENI G, MOSCA C, DE SANTIS S, MONALDI C, POLETTI A, TERRAGNA C, CURTI A, CAVO M, SOVERINI S, OTTAVIANI E. Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets. *Int J Mol Sci*. 2024 Sep 17;25(18):10002. doi: 10.3390/ijms251810002.
60. **MANCINI M**, DE SANTIS S, MONALDI C, CASTAGNETTI F, IEZZA M, IURLO A, CATTANEO D, GALIMBERTI S, CERRANO M, CAPODANNO I, BONIFACIO M, ROSSI M, AGOSTINELLI C, MEGGENDORFER M, HAFERLACH T, CAVO M, GUGLIOTTA G, SOVERINI S. SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia. *Clin Transl Med*. 2025 Apr;15(4):e70163. doi: 10.1002/ctm2.70163.

First author of 80 abstracts submitted to national or international hematology and oncology meetings.

Bologna, 29/10/2025

Manuela Mancini